Article

The polarization of immune cells in the tumour environment by TGF&UF062. Nat Rev Immunol

Yale University School of Medicine, 300 Cedar Street, TAC S-569, PO BOX 208011, New Haven, Connecticut 06520, USA.
Nature Reviews Immunology (Impact Factor: 33.84). 08/2010; 10(8):554-67. DOI: 10.1038/nri2808
Source: OAI

ABSTRACT Transforming growth factor-beta (TGFbeta) is an immunosuppressive cytokine produced by tumour cells and immune cells that can polarize many components of the immune system. This Review covers the effects of TGFbeta on natural killer (NK) cells, dendritic cells, macrophages, neutrophils, CD8(+) and CD4(+) effector and regulatory T cells, and NKT cells in animal tumour models and in patients with cancer. Collectively, many recent studies favour the hypothesis that blocking TGFbeta-induced signalling in the tumour microenvironment enhances antitumour immunity and may be beneficial for cancer therapy. An overview of the current drugs and reagents available for inhibiting TGFbeta-induced signalling and their phase in clinical development is also provided.

Download full-text

Full-text

Available from: Richard A Flavell, Aug 26, 2015
0 Followers
 · 
258 Views
  • Source
    • "In mice models, macrophages present CD11b, F4/80, and colony-stimulating factor-1 receptor (CSF-1R), with F4/80 being the surface proteins for M1 and M2 macrophages [11] [20]. TAMs have the major role in the tumor microenvironment to bear immune inhibitory effect [20] [21]. Tumor cells and the surrounding stoma cells secrete cytokines and growth factors that stimulate TAMs and activate the various expressions, functions, receptor regulations, and secretions of chemokines [22] [23], including antitumor M1 macrophages and protumor M2 macrophages [16, 24–26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The present study showed that oral mushroom beta-glucan treatment significantly increased IFN-γ mRNA expression but significantly reduced COX-2 mRNA expression within the lung. For LLC tumor model, oral Ganoderma lucidum or Antrodia camphorata polysaccharides treatments significantly reduced TGF-β production in serum. In addition, IL-12 and IFN-γ mRNA expression were significantly increased, but IL-6, IL-10, COX-2, and TGF-β mRNA expression were substantially following oral mushroom polysaccharides treatments. The study highlights the efficacious effect of mushroom polysaccharides for ameliorating the immune suppression in the tumor microenvironment. Increased M1 phenotype of tumor-associated macrophages and attenuated M2 phenotype of tumor-associated macrophages could be achieved by ingesting mushroom polysaccharides.
    01/2015; 2015:604385. DOI:10.1155/2015/604385
  • Source
    • "Understanding what is truly relevant for the abrogation of protective immunity in different cancers is needed for implementing more effective antitumor immunotherapies. Transforming growth factor-b (TGF-b) is a lymphocyte inhibitor secreted by multiple cells and frequently overexpressed in aggressive cancers (Flavell et al., 2010; Wrzesinski et al., 2007). Tumors induce dendritic cells (DCs) to secrete TGF-b, promoting regulatory T cell (Treg) expansion and indirect suppression of T cell effectors (Ghiringhelli et al., 2005; Hanks et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor-reactive T cells become unresponsive in advanced tumors. Here we have characterized a common mechanism of T cell unresponsiveness in cancer driven by the upregulation of the transcription factor Forkhead box protein P1 (Foxp1), which prevents CD8(+) T cells from proliferating and upregulating Granzyme-B and interferon-γ in response to tumor antigens. Accordingly, Foxp1-deficient lymphocytes induced rejection of incurable tumors and promoted protection against tumor rechallenge. Mechanistically, Foxp1 interacted with the transcription factors Smad2 and Smad3 in preactivated CD8(+) T cells in response to microenvironmental transforming growth factor-β (TGF-β), and was essential for its suppressive activity. Therefore, Smad2 and Smad3-mediated c-Myc repression requires Foxp1 expression in T cells. Furthermore, Foxp1 directly mediated TGF-β-induced c-Jun transcriptional repression, which abrogated T cell activity. Our results unveil a fundamental mechanism of T cell unresponsiveness different from anergy or exhaustion, driven by TGF-β signaling on tumor-associated lymphocytes undergoing Foxp1-dependent transcriptional regulation.
    Immunity 09/2014; 41(3):427-39. DOI:10.1016/j.immuni.2014.08.012 · 19.75 Impact Factor
  • Source
    • "CRC overexpress TGF-β in a tumor-associated manner [41]. It has been shown that neutralization of TGF-β enhances the antitumor response of NK cells, by causing an accumulation of IFN-γ producing NK cells with IFN-γ preservation of surface NKG2D [42]. Upon cytokine stimulation, NK cells become lymphokine-activated killer (LAK) cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Natural killer (NK) cells are innate immune-system lymphocytes capable of killing tumor cells. They secrete cytokines, including interferon (IFN)-γ, which participate in shaping the initial inflammatory and downstream adaptive immune responses. Its potent immunoregulatory action means that IFN-γ might be beneficial in cases of tumor rejection, but its severe side-effects limit clinical applications. This pilot study compared low-dose IFN-γ prepared by sequential-kinetic-activation (SKA), with standard-dose recombinant (r) IFN-γ, in terms of ex-vivo cytotoxic activity of peripheral blood (PB)-NK cells from colorectal carcinoma (CRC) patients. This was tested against the NK-sensitive K562 cell line and the less-sensitive human CRC Caco-2 and HT-29 cell lines. Twenty primitive non-metastatic CRC patients, five metastatic CRC patients, and thirteen healthy donors were enrolled. PB lymphocytes (PBLs) were exposed to medium alone, SKA-IFN-γ (0.25fg/ml) or rIFN-γ (1ng/ml). NK cell cytolytic activity was examined via short-term (51)Cr-release. Pretreatment of PBL from non-metastatic patients with SKA-IFN-γ caused a significant increase in NK cell cytotoxicity, compared to those from normal donors, although less markedly than pretreatment with rIFN-γ against all three cell lines. In contrast, PBLs from metastatic CRC patients displayed significantly decreased NK-cell activity and responsiveness to both rIFN-γ and SKA-IFN-γ treatments. These results demonstrate in principle the immunomodulatory capacity of low-dose SKA-IFN-γ, and might open the door to the possibility of generating a novel, safe, and feasible approach to enhancing NK-cell antitumor activity in early-stage CRC patients.
    International immunopharmacology 12/2013; 19(1). DOI:10.1016/j.intimp.2013.12.011 · 2.71 Impact Factor
Show more